Eli Lilly’s acquisition of Loxo has added the FDA approved asset VITRAKVI and the early- and mid-stage oncology pipeline assets LOXO-305, LOXO-195, and LOXO-292.
Array BioPharma (ARRY) reported its Q4 2018 and fiscal 2018 earnings results August 14. Its sales rose by ~4.9% YoY (year-over-year) to $35.4 million, missing analysts’ estimate of $38.7 million.
Array BioPharma (ARRY) completed its Phase 1b clinical trial of its investigational drug candidate ARRY-382 in combination with Merck’s (MRK) Keytruda for advanced tumor indications.
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle.
Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.
In 2017, Arrowhead Pharmaceuticals (ARWR) generated revenue of $31.4 million compared to $158,000 in 2016. This increase was attributable to the upfront payments Arrowhead received from Amgen.
Ignyta (RXDX) entered into a licensing agreement with Nerviano Medical Sciences in which Ignyta has exclusive global rights to develop and commercialize entrectinib.
